Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Corporate Update (December 2020)
20 slides from Viyash Scientific's corporate update, Dec 22, 2020
Slide 1: Corporate Update
Corporate Update December 22, 2020
Slide 2: SeQuent Today
SeQuent Today Largest Pureplay 8 Global Animal Health Company Manufacturing Assets 100+ in India, Spain, Germany, Country Presence from India Brazil and Turkey $100 Mn 27 1,000+ Investment in R&D, Commercial APIs FDFs across 12 dosage forms manufacturing & market presence 1,700+ 2.0x Scale USFDA App
Slide 3: The Journey
The Journey Financial Performance FY15 FY20 Particulars FY15 FY20 EM: 21% BUSINESS Markets EM: 100% US & EU: 47% Revenue (₹Mn) 4,654 11,792 Other regulated: 32% EBITDA (₹Mn) 206 1,758 EBITDA Margin (%) 4.4% 14.9% Formulations 250+ 1000+ PRODUCTS PAT (₹ Mn) -107 699 API 9 27 Net Debt to Equity (x) 5.
Slide 4: PIVOTS
New Promoter and Consolidation of Board minority interests PIVOTS Continuity of Sharpening strategy Management Team 4
Slide 5: New Promoter and Board
New Promoter and Board New Promoter and Consolidation of Board minority interests PIVOTS Continuity of Sharpening strategy Management Team 5 5
Slide 6: The Carlyle Group assumed charge as the new promoter
The Carlyle Group assumed charge as the new promoter… Change of control Industry leaders join the Induction of Carlyle Board nominees Carlyle acquired 25.20% and became Dr. Kamal Sharma - Non-Executive Neeraj Bharadwaj & Rahul Mukim the new Promoter on August 17, Chairman and Mr. Milind Sarwate - jo
Slide 7: Well-rounded Board with a global expertise
…leading to well-rounded Board with a global expertise Dr. Kamal K Sharma Non-Executive Chairman Mr. Milind Sarwate Independent Director ▪ All round perspective in global pharma ▪ Expertise in corporate finance, value business creation, effective governance & capability ▪ Expertise in operations, co
Slide 8: Well-rounded Board with a global expertise
…leading to well-rounded Board with a global expertise Mr. Neeraj Bharadwaj Mr. Rahul Mukim Non-Executive Director Non-Executive Director (Carlyle Nominee)) (Carlyle Nominee)) ▪ Expertise in large growth capital & buyout ▪ Expertise in India buyout opportunities, opportunities and scaling up existin
Slide 9: Consolidation of Minority Interests
New Promoter and Board Consolidation of minority interests Consolidation of Minority Interests PIVOTS Continuity of Sharpening strategy Management Team 9 9
Slide 10: Consolidating minority interests globally
Consolidating minority interests globally Consolidation of Subsidiaries Provet Amongst the top 3 and the largest veterinary medicines company in Turkey having market share of ~10% with more than 120 product registrations Source of Funds 8 manufacturing lines in various dosage forms including injecta
Slide 11: Sharpening strategy
New Promoter and Consolidation of Sharpening strategy Board minority interests PIVOTS Continuity of Management Team Sharpening strategy 11 11
Slide 12: Stonehaven & PwC Engagements
Stonehaven & PwC Engagements Stonehaven – Focus on Business Strategy Business Existing Business US Market Other initiatives Increasing wallet share with global leaders for API biz. Develop market entry strategy Drive global portfolio strategy Assessing/driving head-room for Acquisition strategy Acce
Slide 13: Continuity of Management Team
New Promoter and Board Consolidation of minority interests Continuity of Management PIVOTS Team Continuity of Sharpening strategy Management Team 13 13
Slide 14: Led by a stable global leadership team
Led by a stable global leadership team Corporate Head Manish Gupta Tushar Mistry Sharat Narasapur Managing Director Chief Financial Officer Technical Operations since 2014 since 2014 since 2015 Business Head Allen Kelly Jose Nunes Filho Sirjiwan Singh Ashish Kakabalia United States LATAM Technical O
Slide 15: Introduction of new ESOP plan
Introduction of new ESOP plan Empirical research has proven that ESOP companies are more productive, faster growing, more profitable Retaining the management team which drove the and lower turnover – benefits that ultimately accrue growth of SeQuent 1.0 to all shareholders Aligning the leadership to
Slide 16: Salient features of ESOP Scheme Plan 2020
Salient features of ESOP Scheme Plan 2020 The notable characteristics of the Scheme are indicated below: ESOP’s to consist of 3 performance criteria : Retention/continuity, share-holder outcome and Individual targets Initial grant at ₹ 86/- per share, the price paid by Carlyle to acquire controlling
Slide 17: ESOP Scheme: Classes of ESOPs
ESOP Scheme : Classes of ESOPs The Class A Options granted under the Scheme shall vest in 5 (five) equal annual tranches as under: First tranche to vest at the end of 12 months from the date of grant in compliance with SEBI Regulations Class A Subsequent 4 (four tranches) to vest on 8th September of
Slide 18: Accounting Implication of the Scheme
Accounting Implication of the Scheme The accounting for the said scheme is to be done as per the fair value method determined by the Black Scholes model for option valuation The ESOP scheme is expected to be rolled out by February 2021 (subject to share-holder approval) Based on the current market p
Slide 19: Thank You
Thank You 1 9
Slide 20: For details, feel free to contact
For details, feel free to contact: Tushar Mistry Diwakar Pingle Abhishek Singhal Chief Financial Officer Christensen Investor Relations Investor Relations Consultant +91 22 4111 4717 +91 22 4215 0210 [email protected] [email protected] [email protected] Registered Office: 301/A, ‘Dosti
SeQuent Scientific — Corporate Update (December 2020) on 6ix